Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jul:98:102225.
doi: 10.1016/j.ctrv.2021.102225. Epub 2021 May 23.

Exploiting somatic alterations as therapeutic targets in advanced and metastatic cervical cancer

F J Crowley  1 , R E O'Cearbhaill  2 , D C Collins  3
Affiliations
Review

Exploiting somatic alterations as therapeutic targets in advanced and metastatic cervical cancer

F J Crowley et al. Cancer Treat Rev. 2021 Jul.

Abstract

It is estimated that 604,127 patients were diagnosed with cervical cancer worldwide in 2020. While a small percentage of patients will have metastatic disease at diagnosis, a large percentage (15-61%) later develop advanced disease. For this cohort, treatment with systemic chemotherapy remains the standard of care, with a static 5-year survival rate over the last thirty years. Data on targetable molecular alterations in cervical cancer have lagged behind other more common tumor types thus stunting the development of targeted agents. In recent years, tumor genomic testing has been increasingly incorporated into our clinical practice, opening the door for a potential new era of personalized treatment for advanced cervical cancer. The interim results from the NCI-MATCH study reported an actionability rate of 28.4% for the cervical cancer cohort, suggesting a subset of patients may harbor mutations which that are targetable. This review sets out to summarize the key targeted agents currently under exploration either alone or in combination with existing treatments for cervical cancer.

Keywords: Cervical cancer; Mutation; Precision oncology; Targeted therapy.

PubMed Disclaimer

Figures

Fig. 1.
Fig. 1.
Anticancer targets in cervical cancer: focus on EGFR, HER2, VEGF pathways. Made with Biorender.com.
Fig. 2.
Fig. 2.
Mechanism of action of tisotumab vedotin. Made with Biorender.com.
See this image and copyright information in PMC

References

    1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021;n/a. 10.3322/caac.21660. - DOI - PubMed
    1. Arbyn M, Weiderpass E, Bruni L, de Sanjosé S, Saraiya M, Ferlay J, et al. a worldwide analysis. Lancet Glob Heal 2018;2020. 10.1016/S2214-109X(19)30482-6. - DOI - PMC - PubMed
    1. Marth C, Landoni F, Mahner S, McCormack M, Gonzalez-Martin A, Colombo N. Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†; Ann Oncol 2017;28:iv72–83. 10.1093/annonc/mdx220. - DOI - PubMed
    1. Watson M, Saraiya M, Benard V, Coughlin SS, Flowers L, Cokkinides V, et al. Burden of cervical cancer in the United States, 1998–2003. Cancer 2008;113: 2855–64. 10.1002/cncr.23756. - DOI - PubMed
    1. Cancer.net. Cervical Cancer: Statistics n.d.